

Facciamo il punto su...

"Homologous Recombination Deficiency (HRD) e biopsia liquida"

Dialogo tra oncologo e anatomo-patologo

Quali Nuovi Agenti?

SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero - Universitaria di Modena

Policlinico


Laura Cortesi

SS Genetica Oncologica

AOU Policlinico Modena



DNA double-strand break repair mechanisms



GENOMIC INSTABILITY








Figure 1. DNA Damage Response signaling through ATM and ATR




Combinations with immunotherapy may achieve immune-mediated cell death at lower DNA damage thresholds

Cancers with replication stress are sensitive to ATR, CHK1 and WEE1 inhibitors




ATM-depletion in breast cancer cells confers sensitivity to PARPi and anthracycline



Gilardini Montani MS, J Exp Clin Cancer Res. 2013; Suh KJ, Breast Cancer Res Treat. 2016

٠

ATM Inhibitor AZD0156 Potentiates Preclinically Olaparib Responses



A Phase I, Open-Label Study to Assess the Safety, Tolerability,
Pharmacokinetics and Preliminary Efficacy of Ascending Doses
of AZD0156 Monotherapy Or in Combination With irinotecan/FOLFIRI or Olaparib in Patients With Advanced Malignancies (NCT02588105)

Recruitment Completed


Function	CHK1	CHK2
Involved in the response to DNA damage	Yes	Yes
Phosphorylates CDC25 phosphatases and p53	Yes	Yes
Structure	Distinct from CHK2	Distinct from CHK1
Protein half-life	<2 hours	>6 hours
Activated by single-strand DNA breaks only	Yes	No
Phosphorylates BRCA1, PML1 and E2F1	No	Yes
Knockout mice	Embryonic lethal	Viable
Knockout mouse embryonic fibroblasts	Defects in G2 checkpoint	No detectable defects in the G2 checkpoint
Mutations identified in the germline	None	Rare founder mutations identified in different populations with varying frequencies

Equipotent at CHK2 and CHK1*	MDA-MB-231 breast cancer (p53 mutant) MCF-10A breast cancer (p53 wild type)	Abrogation of the G. 5 phase arrest induced by the	111
	development (Albert	topoisomerase Linhibitor SN38 No effect on the SN38-induced G /S phase arrest in pS3 wild- type cells	
CHK2 IC ₁₀ = 183 nM ⁴ CHK1 IC ₁₀ = 725 nM	14.3.35-deficient HCT116 colon cancer Syncytia arrested in G, from fusion of asynchronous HeLa cervical cancer cells	Chemosensitized cells to dosorabicin Provoked mitotic catastrophe	46
CHK2 K = 0.07 nM CHK1 K = 2.2 nM	PANC-1 pancreatic cancer AsPC1 pancreatic cancer HeLa cervical cancer SKOV-3 ovarian cancer	Abrogation of the G, arrest induced by the antimetabolite genicitabine Chemosensitization of PANC-1 xenografts to genicitabine	113
CHK2 K = 37 nM CHK1 IC_>10,000 nM	CD4' and CD8' Tcells from human blood	T cells rescued from γ irradiation-induced apoptosis (inhibitor EC $_{\rm je}$ 3-7 $\mu M)$	118
CHK2 K = 11 nM CHK1 IC ₂₀ >10.000 nM	HCT116 colon cancer (p53 wild type) Bj-hTERT libroblasts EBV-immortalized lymphoblastoid LCL-N cells Isolated mouse thymocytes	Prevented CHK2-dependent, Y-radiation-induced degradation of MDMX protein Protected thymocytes from Y-radiation induced apoptosis	117
CHK2 IC = 240 nM CHK1 IC > 10,000 nM	MCF-7 breast cancer (p53 wild type) HT29 (p53 mutant)	No cellular effects when used in combination with topotec an or camptothecin — attributed to confounding off-target activities and poor cell permeability	115
	CHK1 IC_ = 725 nM CHK2 K = 0.07 nM CHK1 K = 2.2 nM CHK2 K = 37 nM CHK2 K = 37 nM CHK2 K = 11 nM CHK1 IC_ > 10.000 nM CHK1 IC_ > 10.000 nM	CHK1 IC = 725 nM colon cancer Syncytia arrested in G, from husion of asynchronous HeLa cervical cancer cells CHK2 K = 0.07 nM PANC-1 pancreatic cancer CHK1 K = 2.2 nM PANC-1 pancreatic cancer HeLa cervical cancer SKOV-3 ovarian cancer F CHK2 K = 37 nM CD4* and CD8* T cells from human blood CHK2 K = 11 nM CD4* and CD8* T cells from human blood CHK2 K = 11 nM HCT1116 colon cancer (p53 wild type) Bi-hTERT fibeoblasts EBV-immortalized lymphoblistoid UC1-N cells bolated mouse thymocytes CHK2 IC_ = 240 nM MCF-7 breast cancer (p53 wild type) CHK1 IC_ = 10.000 nM MICF-7 breast cancer (p53 wild type)	CHK1 IC = 725 nM colon cancer dexonubicin Syncytia arrested in G, from husion of asynchronous HeLa cervical cancer cells dexonubicin CHK2 K = 0.07 nM PANC-1 pancreatic cancer Abrogation of the G, arrest induced by the antimetabolite genecitabine CHK1 K = 2.2 nM CHK2 K = 37 nM CD4' and CD8' T cells from human blood T cells rescued from y irradiation-induced apoptosis (nhibitor EC 3-7 µM) CHK2 K = 37 nM CD4' and CD8' T cells from human blood T cells rescued from y irradiation-induced apoptosis (nhibitor EC 3-7 µM) CHK2 K = 11 nM HCT116 colon cancer (p53 wild type) Prevented CHK2-dependent, y-adiation of MDMX protein Protected thymocytes from y-radiation induced apoptosis CHK2 K = 11 nM HCT116 colon cancer (p53 wild type) Prevented CHK2-dependent, y-adiation induced apoptosis CHK2 K = 240 nM MCF-7 breast cancer (p53 wild type) No cellular effects when used in combination with topotecan or compionation y-radiation of confourned to confourned to confourned to

*Inhibition determined in a cell-based assay; mzyme inhibition parameters not described, 'Inhibition data from REF, 140, 'Systematic name: 2-(4-(4chlorophenoxylphenyl): 14-benzo(d):midazole: 5-carbonamidu; 'Systematic name: 5-(4-(4-bromophenylamino)phenylamino): 3-bydroxy: N-(1-bydroxypropan-2yl):sothiazole: 4-carbonimidamide; 'Systematic name: QE_2'E): 2.2', '(1,1'-(4,4'-carbonylbistazanediy(bist(6,1-phenylene))bisteriation: 1-yl-1-ylidene)(bist)dydrazinec



What is ATR and why inhibit it?




- ATR is a druggable kinase
- Central to the response to DNA replication fork arrest
- DNA Replication Stress response
- S and G2/M checkpoints
- · Replication fork remodelling/repair
- Many oncogenes and therapies cause Replication Stress
- Cyclin E amplification / TP53 / ATM mutations sensitise to ATRi in vitro

Adapted from Lecona et al Nat Rev Cancer Vol. 18, Iss. 9, 586-595


San Antonio Breast Cancer Symposium®, December 10-14, 2019

Early clinical development of ATR inhibitors




Clinical case: patient #1

- ATM^{100 / WE} ER' / HER2¹⁴² platinum refractory breast cancer with 11 prior lines of therapy
- PR [-54%], duration of treatment 356 days
- BAY 1895344 dose 50 mg BID reduced to 40 mg BID (escalation cohort)



DDR: tumor spectmen with ATM protein loss and an ATM_T23331s*40 (71% aliele frequency) Ratione Availative Field Acceleration




- Cisplatin + M6620 (VX-970) in 1st-3rd line BRCA1/2 wild-type mTNBC
 - Selection of PAM50 basal subtype as surrogate for TP53 deficiency
- ORR 32% 1st 3rd line
- ORR 44% 1st line


- BAY1895344 monotherapy phase I in advanced solid tumors
 - Selection for DDR alterations or ATM loss by IHC
- ORR 30.7% at MTD or above
- Responses durable

Telli ML, et al. ESMO 2017 DeBono J, et al. ASCO 2019

This presentation is the intellectual property of the author/presenter. Contact mtelli@stanford.edu for permission to reprint and/or distribute.


Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors






•

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors



•


Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours



Combination cisplatin D1 and IV ATRi D2/9 inTNBC?

ARTICLE OPEN Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Melinda L. Telli¹, Sara M. Tolaney ^[5], Geoffrey I. Shapiro ^[6], Mark Middleton³, Simon R. Lord ^[6], Hendrik Tobias Arkenau^{4,5}, Andrew Tutt ^[6], Vandana Abramson⁸, Emma Dean^{9,16}, Tufia C. Haddad¹⁰, Robert Wesolowski¹¹, Jordi Ferrer-Playan¹², Thomas Goddemeier¹³, Thomas Grombacher¹³, Jennifer Dong¹⁴, Patricia Fleuranceau-Morel¹⁴, Ivan Diaz-Padilla^{12,17} and Ruth Plummer ^[6]



Some outlier Responders No clear patient . . . selection biomarker yet emerges 0 CB

LOH high leve

LOH inview

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 3

Ceralasertib + olaparib demonstrate clinical activity in patients with PARPi resistance


13 subjects BRCA/HRD

Correline PDCAMUT 60

- Germline BRCA^{MUT} 69% (n=9)
- Somatic BRCA^{MUT} 23% (n=3)
- Positive HRD score 8% (n=1)

Prior PARPi

- 1st line maintenance 8% (n=1)
- 2nd line maintenance 38% (n=5
- Treatment 54% (n=7)



Presented By: Stephanie L. Wethington

#ASCO21 | Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.



Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.





Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor, in patients with DNA damage repair loss-of-function mutant tumors in the Phase 1/2 TRESR trial

Timothy A, Yap, ¹ Ian M. Silverman,² Elisa Fontana,³ Elizabeth Lee,⁴ David R. Spigel,⁵ Martin Højgaard,⁶ Stephanie Lheureux,⁷ Niharika Mettu,⁸ Benedito A. Carneiro,⁹ Louise Carter,¹⁰ Ruth Plummer,¹¹ Joseph D. Schonhoft,² Danielle Ulanet,² Parham Nejad,² Peter Manley,² Jorge S. Reis-Filho,¹² Yi Xu,² Victoria Rimkunas,² Maria Koehler,² Ezra Rosen¹²

Other ATRi also focusing on HRD and Replication Stress

.....

	5d	on/2d off (N=	=25)	3 d on/4 d off (N=95)		
Preferred Term	Grade 3 N (%)	Grade 4 N (%)	All Grade N (%)	Grade 3 N (%)	Grade 4 N (%)	All Grade N (%)
Any TRAE	14 (56.0)	1 (4.0)	22 (88.0)	28 (29.5)	4 (4.2)	81 (85.3)
Anemia	13 (52.0)	0	20 (80.0)	23 (24.2)	0	58 (61.1)
Fatigue	1 (4.0)	0	7 (28.0)	2 (2.1)	0	26 (27.4)
Neutrophil count decreased	3 (12.0)	0	6 (24.0)	10 (10.5)	3 (3.2)*	25 (26.3)
Nausea	0	0	3 (12.0)	0	0	22 (23.2)
Platelet count decreased	2 (8.0)	1 (4.0)	7 (28.0)	5 (5.3)	1 (1.1)**	17 (17.9)
Decreased appetite	0	0	4 (16.0)	0	0	14 (14.7)
Diarrhea	0	0	0	0	0	13 (13.7)
Vomiting	0	0	3 (12.0)	0	0	9 (9.5)
White blood cell count decreased	0	0	1 (4.0)	4 (4.2)	0	11 (11.6)
Dyspnea	0	0	5 (20.0)	0	0	6 (6.3)


Tumor Types, n			
Ovarian	22		
Prostate	21		
Breast	17		
Pancreas	13		
Other ¹	47		
Most Common G	enotvpes. n		
ATM	44		
BRCA1	25		
BRCA2	15		
CDK12	9		
RNAseH2	5		
PALB2	5		
SETD2	5		
Other ²	12		



Molecular responses (≥50% ctDNA decline)



Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer





Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC)





Table 3.

Treatment-Related Adverse Events (> 20% of patients)

Adverse Event	All Grades	Grade 3–5*	
Adverse Event	n (%)	n (%)	
Any	31 (91)	18 (53)	
Nausea	17 (50)	2 (6)	
Diarrhea	12 (35)	7 (21)	
Anemia	10 (29)	4 (12)	
Neutropenia	10 (29)	6 (18)	
Fatigue	9 (26)	0 (0)	
Vomiting	7 (21)	0 (0)	
Tinnitus	7 (21)	0 (0)	

1 death occurred from sepsis possibly related to study therapy.




Hypothesis: Inhibition of key kinases in replication stress—ATR and WEE1—would enhance efficacy of Olaparib

ESMO BREAST CANCER

Abbreviations: ATM, ataxia-telangiectasia mutated; ATR, ataxia telangiectasia and RAD3-related protein; BRCA1/2, breast cancer susceptible gene 1/2; DSB, double-strand break; PARP, poly (adenosine diphosphate-ribose) polymerase; PALB2, partner and localizer of BRCA2; Pol, polymerase; WEE1, mitosis inhibitor protein kinase; RPA, Replication protein A.

VIOLETTE (NCT03330847): STUDY DESIGN AND ACTUAL ENROLMENT

 Open-label, multicentre, phase 2 study: Patients were randomised in the three arms and stratified within each arm by pathogenic or likely pathogenic mutations in genes involved in the HRR pathway, and prior platinum therapy



Slide adapted by discussant Professor Valentina Guarneri

ESMO BREAST CANCER

*n shown here depict planned enrolment. The 3 strata were to be capped to achieve ~150 patients within each stratum (~50 patients per treatment arm). Abbreviations: BD, twice daily; BRCAm, BRCA1/2-mutated; HRRm, homologous recombination repair pathway mutation; OD, once daily; TNBC, triple-negative breast cancer.

PRIMARY ENDPOINT: PFS (BICR)

	Number (%) o	of PFS Events ^a		an PFS, (90% CI)	HR (90% CI)	<i>P</i> -value
	Olaparib	Ceralasertib + Olaparib	Olaparib	Ceralasertib + Olaparib		
All	72/114 (63.2)	73/112 (65.2)	3.6 (2.9–5.4)	5.3 (3.7–5.5)	0.79 (0.59–1.04)	0.1822
BRCAm	23/43 (53.5)	25/40 (62.5)	7.3 (5.5–8.1)	7.4 (5.3–7.8)	1.02 (0.63–1.66)	0.9403
Non-BRCAm HRRm	15/20 (75.0)	14/20 (70.0)	1.9 (1.8–3.6)	3.9 (1.9–7.4)	0.54 (0.28–1.03)	0.1274
Non-HRRm	34/51 (66.7)	34/52 (65.4)	1.9 (1.8–2.9)	3.6 (2.7–3.8)	0.76 (0.50–1.14)	0.2959

^aProgressive disease according to RECIST v1.1.

ESMO BREAST CANCER

Stratum A (BRCAm) and Stratum B (Non-BRCAm HRRm) data were analysed prior to the planned primary analysis due to early closure of the study. Abbreviations: BRCAm, BRCA1/2-mutated; CI, confidence interval; HR, hazard ratio; HRRm, homologous recombination repair pathway mutation; PFS, progression-free survival.

Marginal improvement in ORR and duration in non-HRRmut TNBC


- No significant difference in ORR with olaparib and ceralasertib + olaparib in BRCAm or non-BRCAm HRRm
- ORR was significantly higher in non-HRRm for ceralasertib + olaparib; the clinical significance of this finding is limited due to a lack of benefit in PFS

n/N (%)	Objective R	esponse Rate	OR	90% CI	<i>P</i> -value			Arm 1: Olaparib	Arm 2: Ceralasertib + Olaparib
	Olaparib	Ceralasertib + Olaparib					BRCAm	20.0 (16.0, 32.1)	32.0 (16.1, 56.4)
All	24/114 (21.1)	32/112 (28.6)	1.5 0	0.90-2.51	0.1932	Median	Non-BRCAm	16.8	17.1
0004	19/43	20/40 (50.0)	1.2		DoR	HRRm	(16.3, 17.3)	(12.3, NC)	
BRÇAm	(44.2)	20/40 (50.0)	5	0.61–2.61	0.6090		Non- <i>HRR</i> m	11.4	24.1
Non-BRCAm	2/22 (45 2)	(100 (00 0)	1.4	0.00 0.00	0.0700		Non-maran	(7.1, 15.7)	(15.1, 24.1)
<i>HRR</i> m	3/20 (15.0)	4/20 (20.0)	2	0.36–6.02	0.6769	(wks, 25 th percentile, 75 th percentile)			entile)
Non- <i>HRR</i> m	2/51 (3.9)	8/52 (15.4)	4.4 5	1.30–21.20	0.0425			Adapted	Tutt et al ESMO 022 Abstract 210



Abbreviations: CI, confidence interval; BRCAm, BRCA1/2-mutated; DoR, duration of response; HRRm, homologous recombination repair pathway mutation; OR, odds ratio; ORR, objective response rate; NC, not calculable.


SECONDARY ENDPOINT: SAFETY AND TOLERABILITY BY STRATUM



ESMO BREAST CANCER Data shown as % (n).


Abbreviations: AE, adverse event; BRCAm, BRCA1/2-mutated; HRRm, homologous recombination repair pathway mutation.

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors



Background

- HGSOC is the deadliest gynecologic malignancy in industrialized countries. Approximately 25-30% of HGSOC are deficient in homologous recombination (HR) repair due to BRCA1 or BRCA2 (BRCA1/2) germline or somatic mutations leading to sensitivity to PARP inhibitors (PARPis). However, they eventually progress on PARPis leaving unmet clinical need for novel therapeutic strategies.
- ATR/CHK1-mediated G2/M cell cycle checkpoint is necessary for coordination between DNA damage response and cell cycle control. Targeting of cell cycle signaling is a rational approach to induce DNA damage and tumor cell death.
- Preclinical data suggest ATR or CHK1 inhibitors (CHK1i) induce cell death in BRCA mutant HGSOC by causing replication stress and dysregulation of DNA damage responses. Furthermore, both CHK1i monotherapy and combination with PARPi have shown therapeutic activity against PARPi-resistant BRCA1mutant HGSOC preclinical models.
- We hypothesized that prexasertib (LY2606368), the second generation CHK1i, would result in clinical activity in BRCA mutated HGSOC patients.




- Open label, single arm phase II trial of prexasertib
- RP2D dose 105 mg/m² IV prexasertib every 2 weeks in 28-day cycles
- Patients receive treatment until progression of disease, unacceptable toxicity, or withdrawal of consent

Table 2. Clinical response


Best response	Number of patients (n = 18 evaluable)
CR	1 (5.5%) [41 months]
PR	1 (5.5%) [13+ months]
SD	12 (66.6%)
PD	4 (22.2%)
Response Rate (CR+PR)	2 (11%)
Clinical Benefit Rate (CR+PR+SD ≥ 4 months)	12 (66.6%)

CR=complete response: PR=partial response: SD=stable disease: PD=progressive disease

Figure 2. Best response (n=18 evaluable)




PRIMARY RESISTANCE: PI3K/AKT ACTIVATION IN BRCA1-/-




Kumar A, PNAS 2010

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (adp ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer






Rad51 inhibition using CYT-0851, shows anti-cancer activity in cellular models of breast cancer and acts synergistically with PARP inhibitors



igure 3: Combination of CYT-0851 and olaparib prevents homologous recombination and promotes DNA damage in 4T1 ells (mouse model triple negative breast cancer). (A) Immunofluorescent analysis after ionizing radiation showed ccumulation of yH2AX foci (red) in the nuclei (blue) of combination treated 4T1 cells. (B) Sister chromatid exchange (SCE) ssay was used to examine homologous recombination activity. Images show an example of a metaphase spread with bservable SCE events (blow up image). A reduction in events was observed with CYT-0851 (0.625µM) alone and in ombination with olaparib (2.5µM). (C) Neutral Comet assay performed under non-denaturing conditions resulted in increased ail moment in combination treated cells. Error bars represent SEM * p< 0.05; ** p< 0.01; *** p< 0.001; **** p< 0.001






Figure 5: CYT-0851 and olaparib act synergistically in an *in vitro* model of human breast cancer. A matrix study was CYT-0851 and olaparib in an ER+, BRCA wildtype breast cancer cell line, T47D. (A) Synergy score was calculated with th biological replicates using the highest single agent (HSA) model. Synergy is represented in blue and antagonism is rep (B) Dose response curves that correspond with the synergy analysis. Concentration of CYT-0851 is plotted on the concentration of olaparib is an individual curve. Error bars represent SEM.





Figure 6: CYT-0851 and olaparib act synergistically in an *in vivo* model of human breast cancer. A PDX model of triple cancer (homozygous BRCA mutation/HRD +, RAD51 high expression) was subcutaneously engrafted onto the flanks mice. The tumors were allowed to reach a volume of about 150 mm³ prior to the animals being randomized into groups (vehicle, olaparib 100 mg/kg QD, CYT-0851 80 mg/kg QD, and olaparib + CYT-0851) of five animals each. (A) were measured weekly and graphed over time. (B) Percent tumor growth inhibition was calculated using the mean t

CYT-0851 Efficacy: Change in Tumor Burden





3 partial responses


- 1) DLBCL (Pt 013)
- 2) Follicular lymphoma (Pt 021)
- 3) Soft-tissue sarcoma (Pt 006) (unconfirmed)
- 10 patients had stable disease



#ASCO21 | Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.




Two Pathways Repair Double Strand Breaks during S phase






Synergistic effect of a combination of PARPi and NVB




High POLθ expression is a predictive biomarker for NVB sensitivity.






Mechanism of Action: Inhibition of POLQ with NVB results in increased DSB end resection and increased toxic RAD51 levels



RAD51 IHC

High DSB end resection is a PD biomarker for POLQi response Zatreanu et al, Nat Com 12: 3636, 2021

Predictive Biomarkers for Response to a POLQ inhibitor



Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in *TP53*-Mutant

Cancers

Jeffrey Patterson-Fortin^{1,2}, Arindam Bose^{2,3}, Wei-Chih Tsai², Carter Grochala², Huy Nguyen^{2,3}, Jia Zhou², Kalindi Parmar^{2,3}, Jean-Bernard Lazaro^{2,3}, Joyce Liu¹, Kelsey McQueen^{2,3}, Geoffrey I. Shapiro^{1,3}, David Kozono², and Alan D. D'Andrea^{1,2,3}

Cancer Research 20, 3815, 2022

Summary:

1.Peposertib is a specific inhibitor of DNA-PK and NHEJ

2.CRISPR Screen: sgRNAs to POLQ and other MMEJ genes Results in Synthetic lethality with DNA-PK inhibitors

3.Cancer cells become resistant to DNA-PK inhibitors by Downregulating p53

4.Downregulation of p53 results in increased sensitivity to
 NVB. Provides rationale for combination of DNA-PKi and NVB

Conclusions

- ATMi provides sensitivity to PARPi inducing synthetic lethality in BC cells (Phase I study completed)
- CHEK2 inhibitors abrogate the G1/S cell cycle arrest induced by topoisomerase I inhibitor and gemcitabine
- ATRi bezosertib in addition with gemcitabine +/- cisplatin induces 26 % ORR and 43% SD in BRCAWT TNBC
- ATRi RP-3500 provides ≥ 50% ctDNA decline in 41% of pts in phase I (mostly ATM, BRCA1/2, CDK12 and PALB2m)
- Ceralasertib + Olaparib show a significant improvement in ORR and DoR in non HRR mutated TNBC
- Adavosertib + Olaparib show toxicity grade ≥ 3 in 53% (mostly haematological)
- CHEK1i plus gemcitabine in phase I trial provide ORR in pancreatic and cholangiocarcinomas
- PI3Ki + Olaparib overcome resistance to PARP in BRCA mutated and wtBRCA
- RAD51i in phase I provides SD in about 50% of patients (mostly lymphoma and sarcome)
- Novobiocin inhibits POLQ inducing increased DSB end resection and toxic RAD51 levels
- Novobiocin plus DNA-PK inhibitors induce synthetic lethality in p53 mutant cells